NanoViricides Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.40next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Fiscal First Quarter 2027 Earnings Release (Form 10-Q) | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Balance Quarterly3.4MTarget: Sufficient to fund Phase II Mpox clinical trial in DRC
Accumulated Deficit Quarterly154.8M
Net Property and Equipment (P&E) Assets Quarterly6.5MTarget: Maintain cGMP-capable manufacturing and R&D facility in Shelton, CT
Watch Items
- Phase II Clinical Trial of NV-387 for Mpox in the Democratic Republic of Congo (DRC)Trigger: Initiation of patient dosing and site readinessAction: Monitor CRO (Om Sai Clinical Research) progress and patient enrollment rates
- Phase II Clinical Trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the DRCTrigger: National Ethics Committee and ACOREP regulatory approvalsAction: Prepare and submit clinical trial applications following Pillar Committee approval
- Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for NV-387 in MeaslesTrigger: FDA approval of RPDDAction: Track FDA communication to secure potential Priority Review Voucher (PRV) upon drug approval
Research as of 20 Jun 2026